Therapeutic drug monitoring for promotion of rational medication in the elderly: Overview, challenges and opportunities

Abstract

In the context of rapid development of clinical pharmacy in China, therapeutic drug monitoring (TDM) has become a vital tool for rational medication and is widely concerned. TDM combines the knowledge of pharmacokinetic and pharmacodynamic to optimize individualized drug therapy, which can ensure drug efficacy, avoid excessive accumulation of drug, and reduce drug-drug interaction. Drug therapy in elderly patients is often accompanied by age-related changes in the processes of drug absorption, distribution, metabolism and elimination. The pharmacokinetic and pharmacodynamic behaviors of elderly patients differ significantly from those of normal adult population, which may lead to treatment failure or drug toxicity. TDM allows clinician to optimize dose and provides the most viable approach to individualize therapy. By researching the published literature, it is found that little data are available with respect to the special effect of TDM in elderly patients. Herein, focusing on elderly patients, we summarize types of commonly monitored drugs, therapeutic windows, and track the tends and opportunities of TDM. The purpose of this paper is to call for more attention to TDM in elderly patients. TDM should be implemented for the elderly to overcome age-related differences between dose and plasma concentration, to monitor possible drug-drug interaction, and to guide dose adjustment.

Keywords

Therapeutic drug monitoring / Rational medication / Individualized drug therapy / Elderly patients

Declarations

Not applicable.

Authors' contributions

Not applicable.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

This study was supported by the Capital’s Funds for Health Improvement and Research (CFH) (2024-1-4052) and the National Health Commission Clinical Research Projects for Innovative Drugs (WKZX2023CX210007).

Declaration of Competing Interest

The authors declare that they have no competing interests.

Acknowledgements

We thank all the original authors of the included studies for their wonderful work.

Authors' other information

Not applicable.

References

[1] Department of Economic and Social Affairs, United Nations. World Population Ageing 2017: Highlights. 〈https://www.un.org/en/development/desa/population/publications/pdf/ageing/WPA2017_Highlights.pdf〉.

[2] Rankin A, Cadogan CA, Patterson SM, et al. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2018; 9(9):CD008165. https://doi.org/10.1002/14651858.CD008165.pub4

[3] Davies EA, O'Mahony MS. Adverse drug reactions in special populations - the elderly. Br J Clin Pharmacol. 2015; 80(4):796-807. https://doi.org/10.1111/bcp.12596

[4] Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004; 57(1):6-14. https://doi.org/10.1046/j.1365-2125.2003.02007.x

[5] Radonjić T, Dukić M, Jovanović I, et al. Aging of liver in its different diseases. Int J Mol Sci. 2022; 23(21):13085. https://doi.org/10.3390/ijms232113085

[6] Denic A, Glassock RJ, Rule AD. Structural and functional changes with the aging kidney. Adv Chronic Kidney D. 2016; 23(1):19-28. https://doi.org/10.1053/j.ackd.2015.08.004

[7] Kratz T, Diefenbacher A. Psychopharmacological treatment in older people: avoiding drug interactions and polypharmacy. Dtsch Arztebl Int. 2019; 116(29-30):508-518. https://doi.org/10.3238/arztebl.2019.0508

[8] Grześk G, Stolarek W, Kasprzak M, et al. Therapeutic drug monitoring of digoxin - 20 years of experience. Pharmacol Rep. 2018; 70(1):184-189. https://doi.org/10.1016/j.pharep.2017.08.014

[9] Roberti R, Palleria C, Nesci V, et al. Pharmacokinetic considerations about antiseizure medications in the elderly. Expert Opin Drug Metab Toxicol. 2020; 16(10):983-995. https://doi.org/10.1080/17425255.2020.1806236

[10] Hou JW. The new characteristics and trend of China's population development based on the seventh National population census. Acad Forum. 2019; 44(5):1-14.

[11] Mao D, Li G, Liang M, et al. Dietary patterns and multiple chronic diseases in older adults. Nutr Metab. 2024; 21(1):36. https://doi.org/10.1186/s12986-024-00814-y

[12] Nunes BP, Flores TR, Mielke GI, et al. Multimorbidity and mortality in older adults: a systematic review and meta-analysis. Arch Gerontol Geriatr. 2016; 67:130-138. https://doi.org/10.1016/j.archger.2016.07.008

[13] Pazan F, Wehling M. Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequences. Eur Geriatr Med. 2021; 12(3):443-452. https://doi.org/10.1007/s41999-021-00479-3

[14] Verde Z, García de Diego L, Chicharro LM, et al. Physical performance and quality of life in older adults: is there any association between them and potential drug interactions in polymedicated octogenarians. Int J Environ Res Public Health. 2019; 16(21):4190. https://doi.org/10.3390/ijerph16214190

[15] Carlquist JF, Knight S, Horne BD, et al. Cardiovascular risk among patients on clopidogrel anti-platelet therapy after placement of drug-eluting stents is modified by genetic variants in both the CYP2C19 and ABCB1 genes. Thromb Haemost. 2013; 109(4):744-754. https://doi.org/10.1160/TH12-05-0336

[16] Harmsze AM, van Werkum JW, Hackeng CM, et al. The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Pharmacogenet Genomics. 2012; 22(3):169-175. https://doi.org/10.1097/FPC.0b013e32834ff6e3

[17] Fang Z, Zhang H, Guo J, Guo J. Overview of therapeutic drug monitoring and clinical practice. Talanta. 2024; 266(Pt 1):124996. https://doi.org/10.1016/j.talanta.2023.124996

[18] Johannessen Landmark C, Johannessen SI, Patsalos PN. Therapeutic drug monitoring of antiepileptic drugs: current status and future prospects. Expert Opin Drug Metab Toxicol. 2020; 16(3):227-238. https://doi.org/10.1080/17425255.2020.1724956

[19] Marangon E, Buzzo M, Posocco B, et al. A new high-performance liquid chromatography-tandem mass spectrometry method for the determination of sunitinib and N-desethyl sunitinib in human plasma: Light-induced isomerism overtaking towards therapeutic drug monitoring in clinical routine. J Pharm Biomed Anal. 2020; 179:112949. https://doi.org/10.1016/j.jpba.2019.112949

[20] Verheijen RB, Yu H, Schellens JHM, et al. Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology. Clin Pharmacol Ther. 2017; 102(5):765-776. https://doi.org/10.1002/cpt.787

[21] Chen X, Du L, Liu M. Development, validation, and application of an UPLC-MS/MS method for vancomycin, norvancomycin, methotrexate, paclitaxel, and imatinib analysis in human plasma. Ann Clin Biochem. 2022; 59(4):253-263. https://doi.org/10.1177/00045632221077183

[22] Udomkarnjananun S, Francke MI, De Winter BCM, et al. Therapeutic drug monitoring of immunosuppressive drugs in hepatology and gastroenterology. Best Pract Res Clin Gastroenterol. 2021;54-55:101756. https://doi.org/10.1016/j.bpg.2021.101756

[23] Abdul-Aziz MH, Brady K, Cotta MO, et al. Therapeutic drug monitoring of antibiotics: defining the therapeutic range. Ther Drug Monit. 2022; 44(1):19-31. https://doi.org/10.1097/FTD.0000000000000940

[24] Xiao Y, Xu YK, Pattengale P, et al. A rapid high-performance LC-MS/MS method for therapeutic drug monitoring of voriconazole, posaconazole, fluconazole, and itraconazole in human serum. J Appl Lab Med. 2017; 1(6):626-636. https://doi.org/10.1373/jalm.2016.022756

[25] Biso L, Aringhieri S, Carli M, et al. Therapeutic Drug Monitoring in Psychiatry: Enhancing Treatment Precision and Patient Outcomes. Pharmaceuticals (Basel). 2024; 17(5):642. https://doi.org/10.3390/ph17050642

[26] Italiano D, Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update. Clin Pharmacokinet. 2013; 52(8):627-645. https://doi.org/10.1007/s40262-013-0067-4

[27] Johannessen Landmark C, Baftiu A, Tysse I, et al. Pharmacokinetic variability of four newer antiepileptic drugs, lamotrigine, levetiracetam, oxcarbazepine, and topiramate: a comparison of the impact of age and comedication. Ther Drug Monit. 2012; 34(4):440-445. https://doi.org/10.1097/FTD.0b013e31825ee389

[28] Seyfinejad B, Jouyban A. Overview of therapeutic drug monitoring of immunosuppressive drugs: Analytical and clinical practices. J Pharm Biomed Anal. 2021; 205:114315. https://doi.org/10.1016/j.jpba.2021.114315

[29] Salman B, Al-Khabori M. Applications and challenges in therapeutic drug monitoring of cancer treatment: a review. J Oncol Pharm Pract. 2021; 27(3):693-701. https://doi.org/10.1177/1078155220979048

[30] Mueller-Schoell A, Groenland SL, Scherf-Clavel O, et al. Therapeutic drug monitoring of oral targeted antineoplastic drugs. Eur J Clin Pharmacol. 2021; 77(4):441-464. https://doi.org/10.1007/s00228-020-03014-8

[31] Gotta V, Widmer N, Decosterd LA, et al. Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial. Cancer Chemoth Pharm. 2014; 74(6):1307-1319. https://doi.org/10.1007/s00280-014-2599-1

[32] Crombag MBS, van Doremalen JGC, Janssen JM, et al. Therapeutic drug monitoring of small molecule kinase inhibitors in oncology in a real-world cohort study: does age matter? Brit J Clin Pharmacol. 2018; 84(12):2770-2778. https://doi.org/10.1111/bcp.13725

[33] Zhang Y, Zhang R. Recent advances in analytical methods for the therapeutic drug monitoring of immunosuppressive drugs. Drug Test Anal. 2018; 10(1):81-94. https://doi.org/10.1002/dta.2290

[34] Fassett RG. Current and emerging treatment options for the elderly patient with chronic kidney disease. Clin Interv Aging. 2014; 9:191-199. https://doi.org/10.2147/CIA.S39763

[35] Jacobson PA, Schladt D, Oetting WS, et al. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. Am J Transplant. 2012; 12(12):3326-3336. https://doi.org/10.1111/j.1600-6143.2012.04232.x

[36] Davidneto E, Romano P, Triboni A, et al. Pharmacokinetics of tacrolimus (TAC) in elderly compared to young recipients in the first year after renal transplantation. data from the NEverOLd Trial. Am J Transplant. 2015; 15(3).

[37] Romano P, Agena F, Ebner P. Pharmacokinetics of mycophenolic acid (MPA) in elderly compared to young recipients in the first year after renal transplantation. data from the NEverOLd trial. Am J Transplant. 2015; 15(3).

[38] Mabilat C, Gros MF, Nicolau D, et al. Diagnostic and medical needs for therapeutic drug monitoring of antibiotics. Eur J Clin Microbiol Infect Dis. 2020; 39(5):791-797. https://doi.org/10.1007/s10096-019-03769-8

[39] Koch BCP, Muller AE, Hunfeld NGM, et al. Therapeutic DRug Monitoring of Antibiotics in Critically Ill patients: current practice and future perspectives with a focus on clinical outcome. Ther Drug Monit. 2022; 44(1):11-18. https://doi.org/10.1097/FTD.0000000000000942

[40] Mizokami F, Shibasaki M, Yoshizue Y, et al. Pharmacodynamics of vancomycin in elderly patients aged 75 years or older with methicillin-resistant Staphylococcus aureus hospital-acquired pneumonia. Clin Interv Aging. 2013; 8:1015-1021. https://doi.org/10.2147/CIA.S50238

[41] Dai Y, Wang Y, Zeng Y, et al. Linezolid and the risk of lactic acidosis: data mining and analysis of the FDA Adverse Event Reporting System. J Clin Pharm Ther. 2020; 45(6):1422-1426. https://doi.org/10.1111/jcpt.13245

[42] Cheng CN, Wu CC, Kuo CH, et al. Impact of high plasma concentrations of linezolid in Taiwanese adult patients- therapeutic drug monitoring in improving adverse drug reactions. J Formos Med Assoc. 2021; 120(1 Pt2):466-475. https://doi.org/10.1016/j.jfma.2020.06.011

[43] Tinelli M, Gervasoni C, Piazza M, et al. Is it time to revise linezolid dose in elderly patients? Eur J Clin Pharmacol. 2017; 73(10):1335-1336. https://doi.org/10.1007/s00228-017-2303-6

[44] Piacentino D, Bianchi E, De Donatis D, et al. Therapeutic drug monitoring of antidepressants: an underused but potentially valuable tool in primary care. Front Psychiatry. 2022; 13:867840. https://doi.org/10.3389/fpsyt.2022.867840

[45] Schoretsanitis G, Kane JM, Correll CU, et al. Blood levels to optimize antipsychotic treatment in clinical practice: a joint consensus statement of the American Society of clinical psychopharmacology and the therapeutic drug monitoring task force of the Arbeitsgemeinschaft für Neuropsychopharmakologie Und Pharmakopsychiatrie. 19cs 13169 J Clin Psychiat. 2020; 81(3) https://doi.org/10.4088/JCP.19cs13169

[46] Hiemke C, Bergemann N, Clement HW, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2017; 51(1-02):e1. https://doi.org/10.1055/s-0037-1600991

[47] Castberg I, Westin AA, Skogvoll E, et al. Effects of age and gender on the serum levels of clozapine, olanzapine, risperidone, and quetiapine. Acta Psychiatr Scand. 2017; 136(5):455-464. https://doi.org/10.1111/acps.12794

[48] Tveit K, Hermann M, Waade RB, et al. Use of antidepressants in older people during a 10-year period: an observational study on prescribed doses and serum levels. Drugs Aging. 2020; 37(9):691-701. https://doi.org/10.1007/s40266-020-00784-9

[49] Hansen MR, Kuhlmann IB, Pottegård A, et al. Therapeutic drug monitoring of venlafaxine in an everyday clinical setting: analysis of age, sex and dose concentration relationships. Basic Clin Pharmacol Toxicol. 2017; 121(4):298-302. https://doi.org/10.1111/bcpt.12796

[50] Ostad Haji E, Mann K, Dragicevic A, et al. Potential cost-effectiveness of therapeutic drug monitoring for depressed patients treated with citalopram. Ther Drug Monit. 2013; 35(3):396-401. https://doi.org/10.1097/FTD.0b013e3182885d9d

[51] Aonuma K, Shiga T, Atarashi H, et al. Guidelines for therapeutic drug monitoring of cardiovascular drugs clinical use of blood drug concentration monitoring (JCS 2015) - Digest Version. Circ J. 2017; 81(4):581-612. https://doi.org/10.1253/circj.CJ-66-0138